Genmab
1,583
DKK
-0.28 %
GMAB
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
-0.28%
+4.83%
+6.06%
+9.55%
-14.15%
-20.25%
-24.58%
-6.77%
+4,542.23%
Genmab is a pharmaceutical company. The company specializes in the research and development of antibodies, which are mainly used in the treatment of cancer patients with lymphatic leukemia and solid tumors. Research and development are based on the company's own developed technology platform and operations are held on a global level. Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark.
Read moreMarket cap
104.77B DKK
Turnover
227.31M DKK
Revenue
21.53B
EBIT %
31.14 %
P/E
12.95
Dividend yield-%
-
Financial calendar
12.3
2025
General meeting '25
8.5
2025
Interim report Q1'25
7.8
2025
Interim report Q2'25
ShowingAll content types
Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference
Notice to Convene the Annual General Meeting of Genmab A/S
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
Genmab Publishes 2024 Annual Report
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Aktier i Vælten - Et tilbageblik på bevægelserne i OMXC25 i 2024, og nogle forudsigelser for 2025
Genmab to Hold 2024 R&D Update and ASH Data Review Meeting
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons